| Name | Title | Contact Details |
|---|---|---|
Ashlee Gray |
General Counsel | Profile |
MHI is a Japan-based multinational engineering company that owns and operates businesses in sectors such as energy, transportation and defense.
Automation AMA offers advisory and consulting services to manufacturers, capital equipment OEMs, and investment firms seeking industrial holding targets. For manufacturers, Automation AMA assists in determining optimal processes for automation, facilitates the creation of RFQs (requests for quotes), manages relationships with automation providers, evaluates proposals, and oversees the automation build process. Clients benefit from the expertise of a seasoned automation veteran with almost 3 decades of experience, ensuring a smooth and successful automation project. Automation OEMs and machine builders can access advisory services, board of director roles, fractional CEO, CTO, COO, and CRO services, business development assistance, strategy planning, standardization of manufacturing and engineering processes, and sales leadership and training. Investment firms receive support with target identification, ownership introductions, due diligence, and business process analysis. Automation AMA also provides temporary or full-time CxO leadership or board of director advisory services to complement existing leadership teams. With over 28 years of experience in founding and growing an automation business, Automation AMA is uniquely positioned to understand the challenges faced by business leaders and entrepreneurs on a daily basis. Founded and led by an industry leader in assembly, robotics, and packaging, Automation AMA offers a comprehensive range of services to support clients throughout their automation journey, as well as to refine engineering, sales, operations, and business development functions.
Hyundai Motor Group Metaplant America (HMGMA) is an advanced automotive manufacturing facility located in Ellabell, Georgia. It serves as Hyundais third production hub in the U.S., complementing existing facilities in Alabama and Georgia. Designed as a Software Defined Factory, HMGMA integrates AI and robotics to support Hyundais vision for a technology-driven future in mobility. The facility spans 2,900 acres and will employ over 8,500 workers, with an additional 6,900 jobs created at off-site suppliers. HMGMA aims to produce 500,000 vehicles annually, including electric and hybrid models like the Hyundai IONIQ 5 and IONIQ 9. The plant represents a significant investment of approximately $12.6 billion, marking one of the largest economic development projects in Georgias history. HMGMA also emphasizes sustainability by utilizing hydrogen fuel-cell electric trucks for logistics, showcasing its commitment to environmentally responsible operations. The facility is expected to have a substantial economic impact, creating nearly 40,000 jobs in Georgia and supporting over 570,000 jobs nationwide.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.